These results confirmed the loss of HAT1 expression resulted in the activation of the MAPK pathway by IGF1R, which conferred BRAFi resistance; therefore, IGF1R or ERK1/2 inhibitors represent pharmacologically tractable options for inhibiting the growth of BRAFi-resistant melanoma cells. The gene discussed is MAPK3; the disease is melanoma.